Eli Lilly shares are trading modestly higher pre-market at $1088.85 after Zacks Equity Research selected the company as its “Bull of the Day,” emphasizing its leadership in obesity and diabetes drugs, which generated $24.8 billion year-to-date.
- Zacks highlighted a new deal with the Trump Administration to expand Medicare and Medicaid coverage of GLP-1s for obesity via the TrumpRX BALANCE program, enabling $50/month co-pays starting in 2027.
- Analysts project 41.24% EPS growth in 2026 and noted that the company recently crossed the $1 trillion market-cap mark.
- Separately, insider filings show Lilly Endowment Inc. sold 293,446 shares for approximately $322.38 million on January 7, 2026.